• 5AM Ventures portfolio company Kinaset Therapeutics dosed the first patient in a Phase 2b PANAIRAMA trial of frevecitinib for severe asthma.
• Trial tests three inhaled dose levels in a randomized, double-blind, placebo-controlled design to select a regimen for pivotal development.
• Frevecitinib targets JAK1, JAK2, JAK3, TYK2; prior Phase 1 data showed FeNO reductions with plasma exposure below active systemic levels.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 5AM Ventures LLC published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.